<HashMap><database>biostudies-literature</database><scores><citationCount>0</citationCount><reanalysisCount>0</reanalysisCount><viewCount>44</viewCount><searchCount>0</searchCount></scores><additional><submitter>Morales L</submitter><funding>European Zoonoses anticipation and preparedness initiative</funding><funding>NIAID NIH HHS</funding><funding>Ministry of Science and Innovation of Spain</funding><funding>Ministry of Science an Innovation of Spain</funding><funding>NIH</funding><pagination>344-355</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC5662013</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>21(3)</volume><pubmed_abstract>Severe acute respiratory syndrome coronavirus (SARS-CoV) causes lethal disease in humans, which is characterized by exacerbated inflammatory response and extensive lung pathology. To address the relevance of small non-coding RNAs in SARS-CoV pathology, we deep sequenced RNAs from the lungs of infected mice and discovered three 18-22 nt small viral RNAs (svRNAs). The three svRNAs were derived from the nsp3 (svRNA-nsp3.1 and -nsp3.2) and N (svRNA-N) genomic regions of SARS-CoV. Biogenesis of CoV svRNAs was RNase III, cell type, and host species independent, but it was dependent on the extent of viral replication. Antagomir-mediated inhibition of svRNA-N significantly reduced in vivo lung pathology and pro-inflammatory cytokine expression. Taken together, these data indicate that svRNAs contribute to SARS-CoV pathogenesis and highlight the potential of svRNA-N antagomirs as antivirals.</pubmed_abstract><journal>Cell host &amp; microbe</journal><pubmed_title>SARS-CoV-Encoded Small RNAs Contribute to Infection-Associated Lung Pathology.</pubmed_title><pmcid>PMC5662013</pmcid><funding_grant_id>BIO2013-42869-R</funding_grant_id><funding_grant_id>HHSN266200700010C</funding_grant_id><funding_grant_id>BIO2016-75549-R AEI/FEDER, UE</funding_grant_id><funding_grant_id>0258-3413/HHSN266200700010C</funding_grant_id><funding_grant_id>BIO2010-16705</funding_grant_id><funding_grant_id>2P01AI060699</funding_grant_id><funding_grant_id>IMI_JU_115760</funding_grant_id><funding_grant_id>P01 AI060699</funding_grant_id><pubmed_authors>Morales L</pubmed_authors><pubmed_authors>tenOever BR</pubmed_authors><pubmed_authors>Fernandez-Delgado R</pubmed_authors><pubmed_authors>Oliveros JC</pubmed_authors><pubmed_authors>Enjuanes L</pubmed_authors><pubmed_authors>Sola I</pubmed_authors><view_count>44</view_count></additional><is_claimable>false</is_claimable><name>SARS-CoV-Encoded Small RNAs Contribute to Infection-Associated Lung Pathology.</name><description>Severe acute respiratory syndrome coronavirus (SARS-CoV) causes lethal disease in humans, which is characterized by exacerbated inflammatory response and extensive lung pathology. To address the relevance of small non-coding RNAs in SARS-CoV pathology, we deep sequenced RNAs from the lungs of infected mice and discovered three 18-22 nt small viral RNAs (svRNAs). The three svRNAs were derived from the nsp3 (svRNA-nsp3.1 and -nsp3.2) and N (svRNA-N) genomic regions of SARS-CoV. Biogenesis of CoV svRNAs was RNase III, cell type, and host species independent, but it was dependent on the extent of viral replication. Antagomir-mediated inhibition of svRNA-N significantly reduced in vivo lung pathology and pro-inflammatory cytokine expression. Taken together, these data indicate that svRNAs contribute to SARS-CoV pathogenesis and highlight the potential of svRNA-N antagomirs as antivirals.</description><dates><release>2017-01-01T00:00:00Z</release><publication>2017 Mar</publication><modification>2024-12-04T12:46:18.519Z</modification><creation>2019-03-27T03:00:19Z</creation></dates><accession>S-EPMC5662013</accession><cross_references><pubmed>28216251</pubmed><doi>10.1016/j.chom.2017.01.015</doi></cross_references></HashMap>